



Moderate to severe hidradenitis suppurativa – secukinumab – initial grandfather authority application

When to use this form	Use this form to apply for initial grandfather PBS-subsidised secukinumab for patients with moderate to severe hidradenitis suppurativa who have received non-PBS-subsidised treatment with secukinumab for the same condition prior to 1 June 2024.
Important information	Initial grandfather applications to start PBS-subsidised treatment must be in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.
	Under no circumstances will phone approvals be granted for moderate to severe hidradenitis suppurativa initial grandfather authority applications.
	The information in this form is correct at the time of publishing and may be subject to change.
Continuing treatment	This form is ONLY for initial grandfather treatment.
	A patient may only qualify for PBS-subsidised treatment under this restriction once in a lifetime.
	Applications for continuing treatment must be made in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.
Treatment specifics	The assessment of the patient's response to the course of treatment must be conducted within the time frame specified in the restriction. Where a demonstration of response is not conducted within the required time frame, the patient will be deemed to have failed treatment with that particular PBS-subsidised biological medicine.
	A patient who has experienced a serious adverse reaction of a severity necessitating permanent treatment withdrawal is not considered to have failed treatment with that particular PBS-subsidised biological medicine.
For more information	Go to servicesaustralia.gov.au/healthprofessionals



medicare

PBS

 \square

Moderate to severe hidradenitis suppurativa – secukinumab – initial grandfather authority application

٦

Pa	tient's details	Co	onditions and criteria
1	Medicare card number		o qualify for PBS authority approval, the following conditions nust be met.
2	or Department of Veterans' Affairs card number	7 8	Is the patient being treated by a dermatologist? No Yes Has the patient received non-PBS-subsidised treatment with this drug for this condition prior to 1 June 2024 ? No Yes
3 Pr	First given name Date of birth (DD MM YYYY) Scriber's details	9	Prior to commencing non-PBS-subsidised treatment with this drug for this condition, the patient had failed to achieve an adequate response to: 2 courses of different antibiotics each for 3 months Name of the antibiotic 1 Name of the antibiotic 2
4	Prescriber number		
5	Dr Mr Mrs Miss Ms Other		or 1 course of antibiotics for 3 months and had an adverse reaction or allergy to another antibiotic necessitating permanent treatment withdrawal Name of the antibiotic of 3 months course
6	First given name Business phone number (including area code) Alternative phone number (including area code)		or neither of the above as the patient has a history of adverse reaction or allergy necessitating permanent treatment withdrawal to 2 different antibiotics.



- **10** After 16 weeks of non-PBS-subsidised treatment with this drug for this condition, did the patient demonstrate a response by achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in an abscess and inflammatory nodule (AN) count compared to baseline with no increase in abscesses or draining fistulae?
 - No Ves

as the patient has not been treated with this drug for this condition for 16 weeks or longer

11 Provide patient's Hurley stage grading and AN count (**no more than 4 weeks old** at the time of initiating non-PBS-subsidised treatment with this drug for this condition)

Hurley stage grading	
AN count	

Checklist

12

The relevant attachments need to be provided with this form.

Details of the proposed prescription(s).

Privacy notice

13 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application.

Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at **servicesaustralia.gov.au/privacypolicy**

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at **servicesaustralia.gov.au/hpos**

14 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application.
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
- the information I have provided in this form is complete and correct.

I understand that:

• giving false or misleading information is a serious offence.

I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

Prescriber's signature (only required if returning by post)

Ł

Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- online (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
 or
- by post (signature required) to Services Australia Complex Drugs Programs Reply Paid 9826

HOBART TAS 7001